A THREE-YEAR, MULTI-CENTER, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF LIGELIZUMAB IN PATIENTS WHO COMPLETED LIGELIZUMAB'S PHASE III STUDIES IN FOOD ALLERGY

Registry ID

CQGE031G12303B

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

NOVARTIS PHARMACEUTICALS CANADA INC

Start date

2023-11-01

Last update

2023-05-01

Conditions

• FOOD ALLERGIES

Related clinical trials

• A 15 MONTHS, DOUBLE-BLIND, RANDOMIZED CONTROLLED TRIAL COMPARING 18 WEEKS OF TWO DOSES OF OMALIZUMAB TO PLACEBO TO ACCELERATE A SYMPTOM-DRIVEN ORAL IMMUNOTHERAPY SCHEDULE IN SUBJECTS AGED 6 TO 25 YEARS WITH MULTIPLE FOOD ALLERGIES (BOOM)

View on source registry